{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:47:58Z","timestamp":1791607678281,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["FRQ-356162"],"award-info":[{"award-number":["FRQ-356162"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["FRQ-356162"],"award-info":[{"award-number":["FRQ-356162"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2020-04702"],"award-info":[{"award-number":["RGPIN-2020-04702"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["# PJT 153287, 178210"],"award-info":[{"award-number":["# PJT 153287, 178210"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT: 178385, 438655"],"award-info":[{"award-number":["PJT: 178385, 438655"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["#2023-00356; #2022-01018 and #2019-02397"],"award-info":[{"award-number":["#2023-00356; #2022-01018 and #2019-02397"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["#2017-00915 and #2022-00732"],"award-info":[{"award-number":["#2017-00915 and #2022-00732"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["#201809-2016862"],"award-info":[{"award-number":["#201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C"],"award-info":[{"award-number":["#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["SG-23-1038904 QC"],"award-info":[{"award-number":["SG-23-1038904 QC"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["#FO2017-0243 and #ALZ2022-0006"],"award-info":[{"award-number":["#FO2017-0243 and #ALZ2022-0006"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009408","name":"Fondation Brain Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41380-024-02884-z","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T10:28:10Z","timestamp":1737196090000},"page":"2810-2820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel synaptic markers predict early tau pathology and cognitive deficit in an asymptomatic population at risk of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2567-2768","authenticated-orcid":false,"given":"Jiarui","family":"Ao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1107-6839","authenticated-orcid":false,"given":"Cynthia","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-1105","authenticated-orcid":false,"given":"Daniel","family":"Auld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C. S.","family":"Breitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-4545","authenticated-orcid":false,"given":"Judes","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the PREVENT-AD research group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Breitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Baril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ducharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Montembeault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Spreng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pichet-Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Munter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tedeshi-Dauar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Labont\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Aumont-Rodrigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Loncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"2884_CR1","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/alz.12901","volume":"19","author":"A Wimo","year":"2023","unstructured":"Wimo A, Seeher K, Cataldi R, Cyhlarova E, Dielemann JL, Frisell O, et al. The worldwide costs of dementia in 2019. Alzheimer\u2019s Dement. 2023;19:2865\u201373.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2884_CR2","doi-asserted-by":"crossref","first-page":"15307","DOI":"10.1073\/pnas.1201632109","volume":"109","author":"J Bali","year":"2012","unstructured":"Bali J, Gheinani AH, Zurbriggen S, Rajendran L. Role of genes linked to sporadic Alzheimer\u2019s disease risk in the production of \u03b2-amyloid peptides. Proc Natl Acad Sci USA. 2012;109:15307\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2884_CR3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","volume":"13","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer\u2019s Res Ther. 2021;13:98.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2884_CR4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimer\u2019s Res Ther. 2021;13:80.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2884_CR5","doi-asserted-by":"crossref","unstructured":"Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs Context 2021;10:2021\u20132027.","DOI":"10.7573\/dic.2021-7-3"},{"key":"2884_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","volume":"12","author":"M Colom-Cadena","year":"2020","unstructured":"Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2020;12:21.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2884_CR7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457\u201364.","journal-title":"Ann Neurol"},{"key":"2884_CR8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/alz.12097","volume":"16","author":"AP Mecca","year":"2020","unstructured":"Mecca AP, Chen M-K, O\u2019Dell RS, Naganawa M, Toyonaga T, Godek TA, et al. In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET. Alzheimer\u2019s Dement. 2020;16:974\u201382.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2884_CR9","doi-asserted-by":"crossref","first-page":"338ra366","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al. Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med. 2016;8:338ra366.","journal-title":"Sci Transl Med"},{"key":"2884_CR10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.25395","volume":"85","author":"RA Sperling","year":"2019","unstructured":"Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85:181\u201393.","journal-title":"Ann Neurol"},{"key":"2884_CR11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jamaneurol.2023.3530","volume":"80","author":"RN Taddei","year":"2023","unstructured":"Taddei RN, Perbet R, Mate de Gerando A, Wiedmer AE, Sanchez-Mico M, Connors Stewart T, et al. Tau oligomer\u2013containing synapse elimination by microglia and astrocytes in Alzheimer disease. JAMA Neurol. 2023;80:1209\u201321.","journal-title":"JAMA Neurol"},{"key":"2884_CR12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/alz.12192","volume":"17","author":"AFT Arnsten","year":"2021","unstructured":"Arnsten AFT, Datta D, Del Tredici K, Braak H. Hypothesis: tau pathology is an initiating factor in sporadic Alzheimer\u2019s disease. Alzheimers Dement. 2021;17:115\u201324.","journal-title":"Alzheimers Dement"},{"key":"2884_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-44374-w","volume":"15","author":"N Franzmeier","year":"2024","unstructured":"Franzmeier N, Dehsarvi A, Steward A, Biel D, Dewenter A, Roemer SN, et al. Elevated CSF GAP-43 is associated with accelerated tau accumulation and spread in Alzheimer\u2019s disease. Nat Commun. 2024;15:202.","journal-title":"Nat Commun"},{"key":"2884_CR14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712\u20136.","journal-title":"Science"},{"key":"2884_CR15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/ACO.0000000000000616","volume":"31","author":"B Bie","year":"2018","unstructured":"Bie B, Wu J, Foss JF, Naguib M. An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Curr Opin Anaesthesiol. 2018;31:407\u201314.","journal-title":"Curr Opin Anaesthesiol"},{"key":"2884_CR16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","volume":"100","author":"B Dejanovic","year":"2018","unstructured":"Dejanovic B, Huntley MA, De Mazi\u00e8re A, Meilandt WJ, Wu T, Srinivasan K, et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron. 2018;100:1322\u201336.e1327.","journal-title":"Neuron"},{"key":"2884_CR17","doi-asserted-by":"crossref","first-page":"eaaf6295","DOI":"10.1126\/scitranslmed.aaf6295","volume":"9","author":"Q Shi","year":"2017","unstructured":"Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice. Sci Transl Med. 2017;9:eaaf6295.","journal-title":"Sci Transl Med"},{"key":"2884_CR18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.mam.2008.08.001","volume":"29","author":"DR Edwards","year":"2008","unstructured":"Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Asp Med. 2008;29:258\u201389.","journal-title":"Mol Asp Med"},{"key":"2884_CR19","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1007\/s00018-019-03173-7","volume":"76","author":"H-E Hsia","year":"2019","unstructured":"Hsia H-E, T\u00fcshaus J, Brummer T, Zheng Y, Scilabra SD, Lichtenthaler SF. Functions of \u2018A disintegrin and metalloproteases (ADAMs)\u2019 in the mammalian nervous system. Cell Mol Life Sci. 2019;76:3055\u201381.","journal-title":"Cell Mol Life Sci"},{"key":"2884_CR20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun. 2019;7:169.","journal-title":"Acta Neuropathol Commun"},{"key":"2884_CR21","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s11357-023-00764-y","volume":"45","author":"M Llaurador-Coll","year":"2023","unstructured":"Llaurador-Coll M, Rios S, Garc\u00eda-Gavil\u00e1n JF, Babio N, Vilella E, Salas-Salvad\u00f3 J. Plasma levels of neurology-related proteins are associated with cognitive performance in an older population with overweight\/obesity and metabolic syndrome. Geroscience. 2023;45:2457\u201370.","journal-title":"Geroscience"},{"key":"2884_CR22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, Brinkmalm G, Honer WG, Fr\u00f6lich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:53.","journal-title":"Mol Neurodegener"},{"key":"2884_CR23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","volume":"8","author":"A Brinkmalm","year":"2016","unstructured":"Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H, Bouaziz-Amar E, et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2016;8:41.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2884_CR24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.conb.2020.04.006","volume":"63","author":"AC Wolfes","year":"2020","unstructured":"Wolfes AC, Dean C. The diversity of synaptotagmin isoforms. Curr Opin Neurobiol. 2020;63:198\u2013209.","journal-title":"Curr Opin Neurobiol"},{"key":"2884_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fnsyn.2016.00007","volume":"8","author":"F Antonucci","year":"2016","unstructured":"Antonucci F, Corradini I, Fossati G, Tomasoni R, Menna E, Matteoli M. SNAP-25, a known presynaptic protein with emerging postsynaptic functions. Front Synaptic Neurosci. 2016;8:7.","journal-title":"Front Synaptic Neurosci"},{"key":"2884_CR26","first-page":"236","volume":"3","author":"J Breitner","year":"2016","unstructured":"Breitner J, Poirier J, Etienne P, Leoutsakos J. Rationale and structure for a new center for studies on prevention of Alzheimer\u2019s disease (StoP-AD). J Prev Alzheimer\u2019s Dis. 2016;3:236\u201342.","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"2884_CR27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/alz.12442","volume":"18","author":"C Picard","year":"2022","unstructured":"Picard C, Nilsson N, Labont\u00e9 A, Auld D, Rosa-Neto P, Initiative tAsDN, et al. Apolipoprotein B is a novel marker for early tau pathology in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2022;18:875\u201387.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2884_CR28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jalz.2019.01.015","volume":"15","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3 A, Alcolea D, Mart\u00ednez-Lage P, Scheltens P, Parnetti L, Poirier J, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer\u2019s disease continuum in the BIOMARKAPD study. Alzheimer\u2019s Dement. 2019;15:742\u201353.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2884_CR29","doi-asserted-by":"crossref","first-page":"e1190","DOI":"10.1212\/WNL.0000000000008905","volume":"94","author":"M McSweeney","year":"2020","unstructured":"McSweeney M, Pichet Binette A, Meyer PF, Gonneaud J, Bedetti C, Ozlen H, et al. Intermediate flortaucipir uptake is associated with A\u03b2-PET and CSF tau in asymptomatic adults. Neurology. 2020;94:e1190\u2013200.","journal-title":"Neurology"},{"key":"2884_CR30","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Sch\u00f6ll M, Strandberg O, et al. Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151\u201362.","journal-title":"JAMA"},{"key":"2884_CR31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310\u20139.","journal-title":"J Clin Exp Neuropsychol"},{"key":"2884_CR32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"2884_CR33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ana.24921","volume":"81","author":"BM Tijms","year":"2017","unstructured":"Tijms BM, Bertens D, Slot RE, Gouw AA, Teunissen CE, Scheltens P, et al. Low normal cerebrospinal fluid A\u03b242 levels predict clinical progression in nondemented subjects. Ann Neurol. 2017;81:749\u201353.","journal-title":"Ann Neurol"},{"key":"2884_CR34","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamaneurol.2017.0892","volume":"74","author":"ME Farrell","year":"2017","unstructured":"Farrell ME, Kennedy KM, Rodrigue KM, Wig G, Bischof GN, Rieck JR, et al. Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship. JAMA Neurol. 2017;74:830\u20138.","journal-title":"JAMA Neurol"},{"key":"2884_CR35","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue MC, Sperling RA, Petersen R, Sun C-K, Weiner MW, Aisen PS, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317:2305\u201316.","journal-title":"JAMA"},{"key":"2884_CR36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3233\/JAD-170887","volume":"63","author":"PF Meyer","year":"2018","unstructured":"Meyer PF, Savard M, Poirier J, Labont\u00e9 A, Rosa-Neto P, Weitz TM, et al. Bi-directional association of cerebrospinal fluid immune markers with stage of Alzheimer\u2019s disease pathogenesis. J Alzheimers Dis. 2018;63:577\u201390.","journal-title":"J Alzheimers Dis"},{"key":"2884_CR37","doi-asserted-by":"crossref","first-page":"e16616","DOI":"10.1371\/journal.pone.0016616","volume":"6","author":"X Hu","year":"2011","unstructured":"Hu X, Pickering E, Liu YC, Hall S, Fournier H, Katz E, et al. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer\u2019s disease. PLoS ONE. 2011;6:e16616.","journal-title":"PLoS ONE"},{"key":"2884_CR38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1353\/hub.2010.a389322","volume":"82","author":"M Tremblay","year":"2010","unstructured":"Tremblay M, Vezina H. Genealogical analysis of maternal and paternal lineages in the Quebec population. Hum Biol. 2010;82:179\u201398.","journal-title":"Hum Biol"},{"key":"2884_CR39","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/35042049","volume":"1","author":"L Peltonen","year":"2000","unstructured":"Peltonen L, Palotie A, Lange K. Use of population isolates for mapping complex traits. Nat Rev Genet. 2000;1:182\u201390.","journal-title":"Nat Rev Genet"},{"key":"2884_CR40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13195-023-01336-0","volume":"15","author":"J Goossens","year":"2023","unstructured":"Goossens J, Cervantes Gonz\u00e1lez A, Dewit N, Lid\u00f3n L, Fortea J, Alcolea D, et al. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer\u2019s disease continuum. Alzheimer\u2019s Res Ther. 2023;15:186.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2884_CR41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology. Alzheimer\u2019s Dement. 2019;15:55\u201364.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2884_CR42","volume":"4","author":"M Tzioras","year":"2023","unstructured":"Tzioras M, Daniels MJD, Davies C, Baxter P, King D, McKay S, et al. Human astrocytes and microglia show augmented ingestion of synapses in Alzheimer\u2019s disease via MFG-E8. Cell Rep Med. 2023;4:101175.","journal-title":"Cell Rep Med"},{"key":"2884_CR43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54:412\u201336.","journal-title":"Nat Genet"},{"key":"2884_CR44","doi-asserted-by":"crossref","first-page":"a005710","DOI":"10.1101\/cshperspect.a005710","volume":"4","author":"C L\u00fcscher","year":"2012","unstructured":"L\u00fcscher C, Malenka RC. NMDA receptor-dependent long-term potentiation and long-term depression (LTP\/LTD). Cold Spring Harb Perspect Biol. 2012;4:a005710.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2884_CR45","doi-asserted-by":"crossref","first-page":"101986","DOI":"10.1016\/j.pneurobio.2020.101986","volume":"200","author":"KA Alkadhi","year":"2021","unstructured":"Alkadhi KA. NMDA receptor-independent LTP in mammalian nervous system. Prog Neurobiol. 2021;200:101986.","journal-title":"Prog Neurobiol"},{"key":"2884_CR46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q","volume":"60","author":"QS Chen","year":"2000","unstructured":"Chen QS, Kagan BL, Hirakura Y, Xie CW. Impairment of hippocampal long\u2010term potentiation by Alzheimer amyloid \u03b2\u2010peptides. J Neurosci Res. 2000;60:65\u201372.","journal-title":"J Neurosci Res"},{"key":"2884_CR47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid \u03b2 protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535\u20139.","journal-title":"Nature"},{"key":"2884_CR48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","volume":"26","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Bendlin BB. Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021;26:296\u2013308.","journal-title":"Mol Psychiatry"},{"key":"2884_CR49","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/nn.4328","volume":"19","author":"JW Wu","year":"2016","unstructured":"Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19:1085\u201392.","journal-title":"Nat Neurosci"},{"key":"2884_CR50","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1126\/science.1162844","volume":"321","author":"MA Busche","year":"2008","unstructured":"Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer\u2019s disease. Science. 2008;321:1686\u20139.","journal-title":"Science"},{"key":"2884_CR51","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-190721","volume":"72","author":"PG Kehoe","year":"2019","unstructured":"Kehoe PG, Al Mulhim N, Zetterberg H, Blennow K, Miners JS. Cerebrospinal fluid changes in the renin-angiotensin system in Alzheimer\u2019s disease. J Alzheimers Dis. 2019;72:525\u201335.","journal-title":"J Alzheimers Dis"},{"key":"2884_CR52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/alzrt257","volume":"6","author":"HM Jochemsen","year":"2014","unstructured":"Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI, et al. The association of angiotensin-converting enzyme with biomarkers for Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2014;6:27.","journal-title":"Alzheimer\u2019s Res Ther"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02884-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02884-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02884-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T18:02:54Z","timestamp":1750701774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02884-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2884"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02884-z","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JP serves as a scientific advisor to the Alzheimer Society of France. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).KB has served as a consultant and on advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, and Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. All other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}